<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03955575</url>
  </required_header>
  <id_info>
    <org_study_id>H-18048247</org_study_id>
    <nct_id>NCT03955575</nct_id>
  </id_info>
  <brief_title>Treatment of Bile Acid Malabsorption With Liraglutide</brief_title>
  <acronym>BAM-LIRA</acronym>
  <official_title>Treatment of Bile Acid Malabsorption With Liraglutide</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Filip Krag Knop</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the effect of Liraglutide on bile acid malabsorption, with colesevelam
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of the present study is to provide proof of concept that treatment with
      the GLP-1 receptor agonist liraglutide is efficacious (as assessed by symptom relief, i.e.
      response to treatment) and safe (as assessed by adverse effects) in the management of BAM and
      that it improves bile acid reabsorption (as assessed by SeHCAT) in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in stool fequency</measure>
    <time_frame>7 weeks</time_frame>
    <description>Contestants will use a questionaire, which will be filled out three times during the 7 weeks periode</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total symptoms score, quality of life scores, and biomarker.</measure>
    <time_frame>7 weeks</time_frame>
    <description>Total symptoms score, quality of life scores, and biomarker values will be analysed using a constrained linear mixed model with inherent baseline adjustment and with an unstructured covariance pattern. Changes since baseline within and between groups will be reported with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SeHCAT</measure>
    <time_frame>7 weeks</time_frame>
    <description>Three SeHCAT scans will be made, and the difference will be evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of patients tolerating the treatment and proportion of patients experiencing remission of BAM related diarrhoea</measure>
    <time_frame>7 weeks</time_frame>
    <description>Proportions of patients tolerating the treatment and proportion of patients experiencing remission of BAM related diarrhoea within each group will be reported with exact binomial confidence intervals and compared between groups using risk differences and Fisher's exact test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Bile Acid Malabsorption</condition>
  <arm_group>
    <arm_group_label>Liraglutide/placebo-colesevelam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide as active and colesevelam as placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Liraglutide/colesevelam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide as placebo and colesevelam as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide 6 MG/ML</intervention_name>
    <description>Liraglutide as injections.</description>
    <arm_group_label>Liraglutide/placebo-colesevelam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>3 x 625 miligram 2 times a day.</description>
    <arm_group_label>Placebo-Liraglutide/colesevelam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Caucasian ethnicity

               -  SeHCAT-verified moderate (5-10% bile acid retention after 7 days) or severe BAM
                  (&lt;5% retention)

               -  Normal haemoglobin (for men 8.3-10.5 mmol/L; for women 7.3-9.5 mmol/L)

               -  Age above 18 years and below 75 years

               -  Informed and written consent

               -  BMI &gt;18,5 kg/m2 and &lt;40 kg/m2

               -  Glycated haemoglobin (HbA1c) &lt;48 mmol/mol

        Exclusion Criteria:

          -  • History of or present hepatobiliary disorder (except for non-alcoholic steatotic
             liver disease) and/or alanine aminotransferase (ALAT) and/or serum aspartate
             aminotransferase (ASAT) &gt;3 times upper limit of normal) or history of hepatobiliary
             disorder

               -  Gastrointestinal disease (except for BAM), previous intestinal resection or any
                  major intra-abdomial surgery

               -  Diabetes mellitus

               -  Nephropathy with eGFR &lt; 60 mL/min/1.73m2

               -  Treatment with medicine that cannot be paused for 12 hours

               -  Hypothyroidism or hyperthyroidism, if not well regulated.

               -  Treatment with oral anticoagulants

               -  Active or recent malignant disease

               -  Any treatment or condition requiring acute or sub-acute medical or surgical
                  intervention

               -  Females of child-bearing potential who is pregnant (tested before entering the
                  study), breastfeeding or intend to become pregnant or is not using adequate
                  contraceptive methods, which includes Intrauterine Device (IUD), birth control
                  pills, sexual abstinence or living in a relationship with a sterile partner.

               -  Known or suspected hypersensitivity to trial products or related products

               -  Any condition considered incompatible with participation by the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>filip.krag.knop.01@regionh.dk</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin L Kårhus, MD</last_name>
    <phone>+45 38673551</phone>
    <email>martin.lund.kaarhus@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filip K Knop, MD PhD</last_name>
    <email>filip.krag.knop.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <state>Regionh</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin L Kårhus, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Filip Krag Knop</investigator_full_name>
    <investigator_title>Professor, Consultant Endocrinologist, MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malabsorption Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

